The role of (111)In Capromab Pendetide (Prosta-ScintR) immunoscintigraphy in the management of prostate cancer

Q J Nucl Med. 2002 Jun;46(2):131-7.

Abstract

(111)In Capromab Pendetide (ProstaScintR) is a whole murine antibody that is reactive with prostate specific membrane antigen (PSMA), a glycoprotein on the surface of normal and abnormal prostate epithelium. It has proven to be of great value in assisting management decisions in prostate cancer patients who initially present with high risk for metastatic spread, or who develop a picture of recurrent disease after surgery or radiation therapy. Patterns of metastatic lymphatic spread have correlated well with autopsy reports in the literature. Unfortunately, other imaging study and/or histologic confirmation of scintigraphic findings has been difficult to obtain. Prostascint's role in predicting durable complete response (DCR) in postoperative patients having salvage radiotherapy to their prostate fossa is very promising. Further investigative work in larger patient populations is needed to confirm these early results.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal*
  • Drug Approval
  • False Positive Reactions
  • Follow-Up Studies
  • Humans
  • Lymphatic Metastasis
  • Male
  • Postoperative Care
  • Preoperative Care
  • Prostatic Neoplasms / diagnosis
  • Prostatic Neoplasms / diagnostic imaging*
  • Radioimmunodetection / methods*
  • Radiopharmaceuticals

Substances

  • Antibodies, Monoclonal
  • Radiopharmaceuticals
  • Capromab Pendetide